<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784795</url>
  </required_header>
  <id_info>
    <org_study_id>16209</org_study_id>
    <secondary_id>I6F-MC-JJCD</secondary_id>
    <secondary_id>2015-004421-14</secondary_id>
    <nct_id>NCT02784795</nct_id>
  </id_info>
  <brief_title>A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of the study drug known as LY3039478
      in combination with other anticancer agents in participants with advanced or metastatic solid
      tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of LY3039478</measure>
    <time_frame>Cycle 1 (up to 28 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve (AUC) of LY3039478 in Combination with Taladegib, LY3023414, Abemaciclib, Cisplatin/Gemcitabine, and Gemcitabine/Carboplatin</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (up to 28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Taladegib and its Active Metabolite LSN3185556, in Combination with LY3039478</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (up to 28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of LY3023414 in Combination with LY3039478</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (up to 28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Abemaciclib and its Major Active Metabolites LSN2839567 and LSN3106726, in Combination with LY3039478</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (up to 28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression (Estimated up to 12 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Disease Progression or Death (Estimated up to 12 Months)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">163</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Breast Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>LY3039478 + Taladegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3039478 given orally 3 times per week (TIW) in combination with taladegib given orally daily on a 28 day cycle. A single dose of taladegib will also be given on day 1 during a 3-day lead-in period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3039478 + LY3023414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3039478 given orally TIW in combination with LY3023414 given orally every 12 hours on a 28-day cycle. A single dose of LY3023414 will also be given on day 1 during a 3-day lead-in period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3039478 + Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3039478 given orally TIW in combination with abemaciclib given orally every 12 hours on a 28-day cycle. A single dose of abemaciclib will also be given on day 1 during a 3-day lead-in period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3039478 + Cisplatin/Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3039478 given orally TIW in combination with cisplatin and gemcitabine given as intravenous (IV) infusions on days 1 and 8 of a 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3039478 + Gemcitabine/Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3039478 given orally TIW in combination with gemcitabine and carboplatin given as IV infusions on days 1 and 8 of a 21 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3039478</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3039478 + Taladegib</arm_group_label>
    <arm_group_label>LY3039478 + LY3023414</arm_group_label>
    <arm_group_label>LY3039478 + Abemaciclib</arm_group_label>
    <arm_group_label>LY3039478 + Cisplatin/Gemcitabine</arm_group_label>
    <arm_group_label>LY3039478 + Gemcitabine/Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taladegib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3039478 + Taladegib</arm_group_label>
    <other_name>LY2940680</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3039478 + Abemaciclib</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3039478 + Cisplatin/Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3039478 + Cisplatin/Gemcitabine</arm_group_label>
    <arm_group_label>LY3039478 + Gemcitabine/Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3039478 + Gemcitabine/Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3023414</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3039478 + LY3023414</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For all parts: The participant must be, in the judgment of the investigator, an
             appropriate candidate for experimental therapy after available standard therapies have
             failed to provide clinical benefit for their advanced or metastatic cancer.

               -  For dose escalation for all combinations: The participant must have histological
                  or cytological evidence of cancer, either a solid tumor or a lymphoma, which is
                  advanced or metastatic.

               -  For Part A dose confirmation: All participants must have histological evidence of
                  advanced or metastatic soft tissue sarcoma or breast cancer. Breast cancer
                  participants must have prescreened mutations, amplification, or gene/protein
                  expression alterations related to Notch pathway.

               -  For Part B dose confirmation: All participants must have histological evidence of
                  advanced or metastatic colon cancer or soft tissue sarcoma. Colon cancer
                  participants must have prescreened mutations, amplification, or gene/protein
                  expression alterations related to Notch pathway.

               -  For Part C dose confirmation: All participants must have histological evidence of
                  advanced or metastatic breast cancer and prescreened mutations, amplification, or
                  gene/protein expression alterations related to Notch pathway.

               -  For Part D dose confirmation: All participants must have histological evidence of
                  cholangiocarcinoma and prescreened mutations, amplification, or gene/protein
                  expression alterations related to Notch pathway. Participants must not have
                  received &gt;1 line of prior systemic therapy for metastatic or resectable disease
                  (that is, participants may have received adjuvant gemcitabine and then later
                  gemcitabine/cisplatin for recurrent metastatic disease).

               -  For Part E dose confirmation: All participants must have histological evidence of
                  locally advanced or metastatic triple negative breast cancer (TNBC) and
                  prescreened mutations, amplification, or gene/protein expression alterations
                  related to Notch pathway. Participants must not have received &gt;2 lines of
                  systemic treatment for advanced or metastatic TNBC.

          -  Have adequate organ function.

          -  Have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG)
             scale.

          -  Have discontinued all previous therapies for cancer.

        Exclusion Criteria:

          -  Have current acute leukemia.

          -  Have current or recent (within 3 months of study drug administration) gastrointestinal
             disease with chronic or intermittent diarrhea, or disorders that increase the risk of
             diarrhea, such as inflammatory bowel disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>858-534-8399</phone>
    </contact>
    <investigator>
      <last_name>Razelle Kurzrock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-243-1287</phone>
    </contact>
    <investigator>
      <last_name>Jaime Merchan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-632-6992</phone>
    </contact>
    <investigator>
      <last_name>Khanh Do</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>313-576-8411</phone>
    </contact>
    <investigator>
      <last_name>Amy Weise</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-888-4163</phone>
    </contact>
    <investigator>
      <last_name>William Tap</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-563-5844</phone>
    </contact>
    <investigator>
      <last_name>Shubham Pant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://lillytrialguide.com/en/studies/solid-tumor/JJCD#?postal=</url>
    <description>Click here for more information about this study:A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Notch Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

